NCT06119997 Screening for Advanced Liver Fibrosis Using Non-invasive Tests in Primary Care
| NCT ID | NCT06119997 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Grenoble |
| Condition | Hepatic Fibrosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-06-26 |
| Primary Completion | 2028-04-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2025-06-26 with a primary completion date of 2028-04-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Liver fibrosis screening is possible at the asymptomatic stage through a healthcare management strategy currently recommended for patients with risk factors for chronic liver disease. It is based on a sequential strategy involving a 1st-line test, fibrosis score calculation (FIB-4). Given this opportunity to identify advanced fibrosis in asymptomatic patients, the project aims to set up this screening program in the Grenoble area with Biogroup Laboratories, in collaboration with the Hepato-gastroenterology department (HGE) of Grenoble University Hospital. The aim of this study is to evaluate the success of sequential screening using FIB-4, followed by a specialized fibrosis test for the diagnosis of advanced hepatic fibrosis
Eligibility Criteria
Inclusion Criteria: * Patients between 18 and 70 years of age * FIB-4 2.67 * Patients covered by Health Insurance System Exclusion Criteria: * Prescription triggering FIB-4 emanate from a hepatogastroenterologist or oncologist * Conditions associated with high risk false-positive FIB-4: ASAT or ALAT \> 300 IU/L, platelets \<50 G/L or \>500 G/L. * Patient refusing to participate * Subjects under guardianship or deprived of liberty
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06119997 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Hepatic Fibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06119997 currently recruiting?
Yes, NCT06119997 is actively recruiting participants. Contact the research team at ccostentin@chu-grenoble.fr for enrollment information.
Where is the NCT06119997 trial being conducted?
This trial is being conducted at Grenoble, France.
Who is sponsoring the NCT06119997 clinical trial?
NCT06119997 is sponsored by University Hospital, Grenoble. The trial plans to enroll 500 participants.